Novo Ventures company plans to fetch USD 127.5m on the US stock exchange

The newly founded spinout company Vectivbio, which Novo Ventures has invested millions of kroner in, has announced that it is getting listed in the US with the goal of fetching USD 127.5m for developing a treatment for short bowel syndrome, which Zealand Pharma is also banking on.
Novo Ventures Senior Partner Naveed Siddiqi | Photo: Novo Ventures / PR
Novo Ventures Senior Partner Naveed Siddiqi | Photo: Novo Ventures / PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

The battle for the short bowel syndrome market is getting tougher.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading